Logo image of PACS

PACS GROUP INC (PACS) Stock Fundamental Analysis

NYSE:PACS - New York Stock Exchange, Inc. - US69380Q1076 - Common Stock - Currency: USD

14.33  0 (0%)

Premarket: 14.33 0 (0%)

Fundamental Rating

3

PACS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 109 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of PACS have multiple concerns. PACS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year PACS was profitable.
PACS Yearly Net Income VS EBIT VS OCF VS FCFPACS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

PACS has a better Return On Assets (2.90%) than 70.37% of its industry peers.
Looking at the Return On Equity, with a value of 19.73%, PACS belongs to the top of the industry, outperforming 90.74% of the companies in the same industry.
With a Return On Invested Capital value of 4.38%, PACS perfoms like the industry average, outperforming 53.70% of the companies in the same industry.
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROIC 4.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PACS Yearly ROA, ROE, ROICPACS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 50 100 150 200

1.3 Margins

PACS has a better Profit Margin (3.63%) than 77.78% of its industry peers.
Looking at the Operating Margin, with a value of 6.68%, PACS is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
PACS has a Gross Margin of 21.33%. This is comparable to the rest of the industry: PACS outperforms 42.59% of its industry peers.
Industry RankSector Rank
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PACS Yearly Profit, Operating, Gross MarginsPACS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 5 10 15 20

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PACS is destroying value.
Compared to 1 year ago, PACS has about the same amount of shares outstanding.
Compared to 1 year ago, PACS has a worse debt to assets ratio.
PACS Yearly Shares OutstandingPACS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 50M 100M
PACS Yearly Total Debt VS Total AssetsPACS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 1B 2B 3B

2.2 Solvency

PACS has an Altman-Z score of 1.51. This is a bad value and indicates that PACS is not financially healthy and even has some risk of bankruptcy.
PACS has a worse Altman-Z score (1.51) than 60.19% of its industry peers.
PACS has a Debt/Equity ratio of 0.90. This is a neutral value indicating PACS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.90, PACS is not doing good in the industry: 63.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Altman-Z 1.51
ROIC/WACC0.52
WACC8.36%
PACS Yearly LT Debt VS Equity VS FCFPACS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

PACS has a Current Ratio of 1.71. This is a normal value and indicates that PACS is financially healthy and should not expect problems in meeting its short term obligations.
PACS's Current ratio of 1.71 is fine compared to the rest of the industry. PACS outperforms 62.04% of its industry peers.
PACS has a Quick Ratio of 1.71. This is a normal value and indicates that PACS is financially healthy and should not expect problems in meeting its short term obligations.
PACS has a better Quick ratio (1.71) than 64.81% of its industry peers.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
PACS Yearly Current Assets VS Current LiabilitesPACS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

PACS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
PACS shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.47%.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.28%
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%

3.2 Future

The Earnings Per Share is expected to grow by 41.62% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 19.34% on average over the next years. This is quite good.
EPS Next Y40.21%
EPS Next 2Y54.73%
EPS Next 3Y41.62%
EPS Next 5YN/A
Revenue Next Year30.36%
Revenue Next 2Y23.43%
Revenue Next 3Y19.34%
Revenue Next 5YN/A

3.3 Evolution

PACS Yearly Revenue VS EstimatesPACS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B 5B
PACS Yearly EPS VS EstimatesPACS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 18.86 indicates a rather expensive valuation of PACS.
75.00% of the companies in the same industry are more expensive than PACS, based on the Price/Earnings ratio.
PACS is valuated rather cheaply when we compare the Price/Earnings ratio to 28.47, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 7.84, the valuation of PACS can be described as very cheap.
95.37% of the companies in the same industry are more expensive than PACS, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of PACS to the average of the S&P500 Index (92.74), we can say PACS is valued rather cheaply.
Industry RankSector Rank
PE 18.86
Fwd PE 7.84
PACS Price Earnings VS Forward Price EarningsPACS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PACS is valued a bit cheaper than the industry average as 69.44% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11.49
PACS Per share dataPACS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

PACS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PACS's earnings are expected to grow with 41.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.47
PEG (5Y)N/A
EPS Next 2Y54.73%
EPS Next 3Y41.62%

More info and screens

0

5. Dividend

5.1 Amount

PACS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACS GROUP INC

NYSE:PACS (2/4/2025, 8:04:01 PM)

Premarket: 14.33 0 (0%)

14.33

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners21.65%
Inst Owner Change1.57%
Ins Owners72.29%
Ins Owner Change-16.67%
Market Cap2.22B
Analysts83.08
Price Target33.08 (130.84%)
Short Float %9.15%
Short Ratio4.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.28%
Min EPS beat(2)24.18%
Max EPS beat(2)56.37%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.83%
Min Revenue beat(2)2.62%
Max Revenue beat(2)5.03%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.36%
PT rev (3m)-23.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.06%
EPS NY rev (1m)0%
EPS NY rev (3m)12.9%
Revenue NQ rev (1m)0.3%
Revenue NQ rev (3m)0.4%
Revenue NY rev (1m)1.02%
Revenue NY rev (3m)1.25%
Valuation
Industry RankSector Rank
PE 18.86
Fwd PE 7.84
P/S 0.71
P/FCF N/A
P/OCF N/A
P/B 3.89
P/tB 4.39
EV/EBITDA 11.49
EPS(TTM)0.76
EY5.3%
EPS(NY)1.83
Fwd EY12.76%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS20.05
BVpS3.69
TBVpS3.27
PEG (NY)0.47
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROCE 6.06%
ROIC 4.38%
ROICexc 4.47%
ROICexgc 4.56%
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Debt/EBITDA 2.21
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z 1.51
F-ScoreN/A
WACC8.36%
ROIC/WACC0.52
Cap/Depr(3y)671.95%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.28%
EPS Next Y40.21%
EPS Next 2Y54.73%
EPS Next 3Y41.62%
EPS Next 5YN/A
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%
Revenue Next Year30.36%
Revenue Next 2Y23.43%
Revenue Next 3Y19.34%
Revenue Next 5YN/A
EBIT growth 1Y-9.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year85.84%
EBIT Next 3Y38.44%
EBIT Next 5YN/A
FCF growth 1Y-74.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.22%
OCF growth 3YN/A
OCF growth 5YN/A